A prospective analysis of the outcome of levetiracetam in clinical practice

Neurology

Volumn 63, Issue 3, 2004, Pages 568-570

  Nicolson, Andrew ^a   Lewis, Sheila A ^b   Smith, David F ^c  

^a HOPE HOSPITAL   (United Kingdom)

^b WREXHAM MAELOR HOSPITAL   (United Kingdom)

^c WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM; LAMOTRIGINE; TOPIRAMATE; VIGABATRIN;

ANTICONVULSANT THERAPY; ARTICLE; ASTHENIA; BEHAVIOR DISORDER; CLINICAL TRIAL; DIZZINESS; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EPILEPSY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; REMISSION; RISK FACTOR; SEDATION; SIDE EFFECT; SOMNOLENCE; TITRIMETRY; TREATMENT OUTCOME;

EID: 3543126543     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000133214.78602.B3     Document Type: Article

References (10)

1. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41:1179-1186.
2. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242.
3. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41:1276-1283.
4. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. Am Stat Assoc J 1958;53:457-481.
5. Krakow K, Walker M, Otoul C, Sander JWAS. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001;56:1772-1774.
6. Schapel G, Chadwick DW. A survey comparing lamotrigine and vigabatrin in everyday clinical practice. Seizure 1996;5:267-270.
7. Kellett MW, Smith DF, Stockton PA, Chadwick DW. Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999;66:759-763.
8. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 2003;61:1218-1221.
9. Gower AJ, Hirsch E, Boehrer A, Noyer M, Marescaux C. Effects of levetiracetem, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 1995;22:207-213.
10. Loescher W, Reissmuller E, Ebert U. Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats. Epilepsy Res 1999;40:63-77.